{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:00:48Z","timestamp":1770040848785,"version":"3.49.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":833,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim and Eli Lilly"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Empagliflozin has been shown to reduce the risk of adverse cardiovascular outcomes in patients with type 2 diabetes and in those with heart failure. The impact of empagliflozin in post-acute myocardial infarction (AMI) patients is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Study to Test the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction (EMPACT-MI) trial screened 6610 participants with AMI and randomized 6522 to empagliflozin or placebo in addition to standard of care. The median (interquartile) age was 64 (56\u201371) years and 75.1% of patients were male. Major comorbidities included hypertension (69.1%), type 2 diabetes (31.7%), prior myocardial infarction (13.0%), and atrial fibrillation (10.9%). The majority (74.3%) of patients presented with an ST-elevation myocardial infarction. Overall, 56.9% of patients had acute signs or symptoms of congestion requiring treatment and 78.3% had left ventricular systolic dysfunction with ejection fraction &amp;lt;45%. Clinical characteristics, including baseline demographics, rates of revascularization, and cardiovascular medications at discharge were largely comparable to recent trials of the post-AMI population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2990","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T05:15:56Z","timestamp":1692940556000},"page":"1708-1715","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial"],"prefix":"10.1093","volume":"25","author":[{"given":"Josephine","family":"Harrington","sequence":"first","affiliation":[{"name":"Division of Cardiology, Duke University Department of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke University Medical Center, Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, all at University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Schuyler","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Department of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke University Medical Center, Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]},{"name":"Institute of Heart Disease, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut Robert","family":"Andersen","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Norway KS , Asker ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Sumin","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Zwiener","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co KG , Ingelheim ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Department of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke University Medical Center, Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi , Jackson, MS ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"2026010913104879500_ejhf2990-bib-0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijcard.2017.05.086","article-title":"Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study","volume":"248","author":"Desta","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0002","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0003","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"2026010913104879500_ejhf2990-bib-0004","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0005","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2026010913104879500_ejhf2990-bib-0006","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0007","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0008","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0009","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"ACCF\/AHA Guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"2013","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0010","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0013","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0014","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0016","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0018","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913104879500_ejhf2990-bib-0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jchf.2022.02.008","article-title":"Acute decompensated heart failure in the setting of acute coronary syndrome","volume":"10","author":"Harrington","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026010913104879500_ejhf2990-bib-0020","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0021","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","volume":"253","author":"Harrington","year":"2022","journal-title":"Am Heart J"},{"key":"2026010913104879500_ejhf2990-bib-0022","doi-asserted-by":"crossref","first-page":"70D","DOI":"10.1016\/0002-9149(91)90263-K","article-title":"Rationale, design and baseline characteristics of the Survival and Ventricular Enlargement Trial. SAVE Investigators","volume":"68","author":"Moy\u00e9","year":"1991","journal-title":"Am J Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9149(99)80791-7","article-title":"Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study","volume":"76","author":"K\u00f8ber","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0024","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1388-9842(03)00112-0","article-title":"VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context","volume":"5","author":"Velazquez","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026010913104879500_ejhf2990-bib-0025","volume-title":"Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack","author":"ClinicalTrials.gov"},{"key":"2026010913104879500_ejhf2990-bib-0026","article-title":"Use of guideline-directed medical therapy in patients with ST-elevation myocardial infarction","volume":"12","author":"Latifi","year":"2020","journal-title":"Cureus"},{"key":"2026010913104879500_ejhf2990-bib-0027","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA Guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026010913104879500_ejhf2990-bib-0028","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2017.11.025","article-title":"2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"71","author":"Yancy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0029","volume-title":"Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability","author":"US Food and Drug Administration","year":"2022"},{"key":"2026010913104879500_ejhf2990-bib-0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cpcardiol.2018.11.002","article-title":"Increasing diversity in clinical trials: Overcoming critical barriers","volume":"44","author":"Clark","year":"2019","journal-title":"Curr Probl Cardiol"},{"key":"2026010913104879500_ejhf2990-bib-0031","volume-title":"Advancing the Science of Engagement PCORI Funding Announcement \u2013 Cycle 1 2023","author":"Patient-Centered Outcomes Research Institute"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1708\/65559848\/eurjhf_25_9_1708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/9\/1708\/65559848\/eurjhf_25_9_1708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:13:32Z","timestamp":1767982412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/9\/1708\/8341920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,25]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2990","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"2023-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}